Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Diffuse large B cell lymphoma (DLBCL) consists of at least 3 distinct molecular subtypes based on its cell of origin (COO): the activated B cell –like (ABC), the germinal center B cell–like (GCB), and primary mediastinal B cell–like subtypes [1]. Of these, the non-GCB subtype, generally classified by immunohistochemical staining and consisting predominantly of the ABC subtype, carries worse prognosis than the GCB subtype because of its resistance to CHOP-like chemotherapy regimens [2-4]. To improve patient outcome, therapeutic strategies targeting the known pathobiology of ABC DLBCL, specifically constitutive activation of the NF-κB signaling cascade, are being developed.

Source: Biology of Blood and Marrow Transplantation - August 25, 2017 Category: Hematology Authors: Yi-Shan Lee, Jingxia Liu, Kristine A. Fricano, Erika M. Webb, Dan R. Toolsie, Sara Jones, James A. Rhoads, Ravi Vij, Amanda F. Cashen, Camille N. Abboud, Peter Westervelt, Nancy L. Bartlett, John F. Dipersio, Friederike H. Kreisel, Kian-Huat Lim Source Type: research